A 6-year-old girl from a low-income urban settlement in Delhi presents with bilateral eye discharge and mild eye irritation for 3 weeks. On examination, she has follicles on the upper tarsal conjunctiva and mild papillary hypertrophy. The upper limbus appears clear. A conjunctival swab is sent for testing. Which organism is most likely responsible, and what is the most appropriate antibiotic for this stage of trachoma?

Explanation

## Diagnosis and Management of Active Trachoma (TF Stage) ### Clinical Features Indicating TF (Trachomatous Inflammation–Active) - **Age:** 6-year-old child (trachoma most common in children <5 years) - **Duration:** 3 weeks (acute/subacute presentation) - **Bilateral eye discharge** (hallmark of chlamydial infection) - **Follicles on upper tarsal conjunctiva** (pathognomonic for trachoma) - **Mild papillary hypertrophy** (active inflammation) - **Clear limbus** (no pannus yet; early stage) These findings are diagnostic of **TF (Trachomatous inflammation–active)**. ### Etiologic Agent: *Chlamydia trachomatis* **Key Point:** *Chlamydia trachomatis* serovars A, B, Ba, and C cause trachoma. It is an obligate intracellular gram-negative bacterium that cannot be cultured on routine media — diagnosis is clinical or by PCR/immunofluorescence. **High-Yield:** Trachoma is the **leading infectious cause of blindness worldwide** and the **leading preventable cause of blindness**. It is endemic in areas with poor sanitation and limited access to clean water. ### Treatment of Active Trachoma (TF) | Regimen | Indication | Efficacy | |---------|-----------|----------| | **Azithromycin single dose (20 mg/kg)** | **TF stage (active inflammation)** | **>95% cure rate; WHO-recommended** | | Tetracycline 1% eye ointment × 6 weeks | Older regimen; poor compliance | 70–80% efficacy | | Doxycycline oral (if >8 years) | Systemic therapy option | Alternative | | Erythromycin eye ointment | Neonatal prophylaxis | Prevents ophthalmia neonatorum | **Clinical Pearl:** Azithromycin is now the **gold standard** for TF because: 1. Single-dose oral therapy → excellent compliance 2. Systemic absorption → treats chlamydial infection at all sites 3. Covers concurrent bacterial superinfection (common in endemic areas) 4. WHO and CDC recommend it for mass drug administration (MDA) campaigns ### Why Tetracycline Is No Longer First-Line - Requires 6 weeks of topical application (poor compliance in endemic areas) - Contraindicated in children <8 years (tetracycline staining of permanent teeth) - Lower cure rates than azithromycin ### Pathophysiology of Trachoma Progression ```mermaid flowchart TD A["Chlamydia trachomatis infection<br/>(serovars A-C)"]:::outcome A --> B["TF: Active inflammation<br/>(follicles, papillary hypertrophy)"]:::outcome B -->|"Untreated or<br/>reinfection"| C["TI: Intense inflammation<br/>(obscured vessels, severe papillae)"]:::outcome C --> D["TS: Scarring<br/>(conjunctival fibrosis, Arlt's line)"]:::outcome D --> E["TT: Trichiasis<br/>(inturned lashes, entropion)"]:::outcome E --> F["Blindness<br/>(corneal opacity)"]:::urgent B -->|"Azithromycin<br/>single dose"| G["Cure<br/>No progression"]:::action style A fill:#e8f4f8 style G fill:#d4edda ``` **Mnemonic for Trachoma Stages:** **"FITS"** - **F** = Follicles (TF) - **I** = Intense inflammation (TI) - **T** = Trichiasis (TT) - **S** = Scarring (TS) (Note: This is a memory aid; the actual WHO classification uses TF, TI, TS, TT in a different order of progression.)